Publications by authors named "Peter Riebling"
Article Synopsis
- ROR1 is an oncofetal protein linked to various cancers, and Zilovertamab vedotin (ZV) is a targeted treatment combining an antibody for ROR1 and a cytotoxic drug, tested in patients with lymphoid cancers.
- In a phase 1 study with 32 patients who had undergone multiple prior therapies, ZV was administered every 3 weeks, starting from various dose levels, with side effects mostly being neutropenia and neuropathy.
- Results showed significant tumor responses, particularly in patients with mantle cell lymphoma and diffuse large B-cell lymphoma, supporting ROR1's potential as a targeted treatment strategy in cancer therapy.
Background: Duchenne muscular dystrophy (DMD) is a severe, progressive, and rare neuromuscular, X-linked recessive disease. Dystrophin deficiency is the underlying cause of disease; therefore, mutation-specific therapies aimed at restoring dystrophin protein production are being explored. We aimed to assess the efficacy and safety of ataluren in ambulatory boys with nonsense mutation DMD.
View Article and Find Full Text PDFPTC299 is a novel small molecule that specifically blocks the production of protein from selected mRNAs that under certain conditions use noncanonical ribosomal translational pathways. Hypoxia, oncogenic transformation, and viral infections limit normal translation and turn on these noncanonical translation pathways that are sensitive to PTC299. Vascular endothelial cell growth factor (VEGF) is an example of a transcript that is posttranscriptionally regulated.
View Article and Find Full Text PDF